Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bégo-Le Bagousse G, Lu Y, Rizova E, Graham NMH, Pirozzi G, De Bruin-Weller M, Eckert L. Ariëns LFM, et al. Acta Derm Venereol. 2019 Sep 1;99(10):851-857. doi: 10.2340/00015555-3219. Acta Derm Venereol. 2019. PMID: 31099402 Free article.
Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Potent Topical Corticosteroids.
Ariëns LFM, van der Schaft J, Stades AME, van de Woestijne AA, De Bruin-Weller MS. Ariëns LFM, et al. Acta Derm Venereol. 2018 Jun 8;98(6):601-602. doi: 10.2340/00015555-2936. Acta Derm Venereol. 2018. PMID: 29881868 Free article. No abstract available.
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.
Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, van Wijk F, Knol EF, Balak DMW, van Dijk MR, de Bruin-Weller MS. Bakker DS, et al. Among authors: ariens lfm. Br J Dermatol. 2019 May;180(5):1248-1249. doi: 10.1111/bjd.17538. Epub 2019 Feb 4. Br J Dermatol. 2019. PMID: 30597515 Free PMC article. No abstract available.
Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
Achten R, Bakker D, Ariens L, Lans A, Thijs J, van der Schaft J, de Boer J, Balak D, de Graaf M, van Luijk C, de Bruin-Weller M. Achten R, et al. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1389-1392.e2. doi: 10.1016/j.jaip.2020.09.042. Epub 2020 Oct 7. J Allergy Clin Immunol Pract. 2021. PMID: 33038589 Free article. No abstract available.
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31. Allergy. 2020. PMID: 31593343
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Spekhorst LS, Ariëns LFM, van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ, de Ridder I, Sloeserwij A, Romeijn GLE, de Graaf M, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Spekhorst LS, et al. Among authors: ariens lfm. Allergy. 2020 Sep;75(9):2376-2379. doi: 10.1111/all.14324. Epub 2020 May 5. Allergy. 2020. PMID: 32302412 Free PMC article. No abstract available.
16 results